Medical Oncologist
CION Cancer Clinics
Why RAS and BRAF testing comes before colon cancer treatment | CION Cancer Clinics
If colon cancer has spread, your oncologist needs RAS and BRAF results before choosing the first plan. Drugs like cetuximab and panitumumab work only when RAS is normal, and a BRAF V600E change needs a different approach. This page explains what each result means, why the wait is usually worth it, and what happens if treatment has to start sooner. At CION Cancer Clinics, our team goes through your reports with you and plans the next test or treatment step.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Why does my oncologist want RAS and BRAF results before starting?
- What does each RAS and BRAF result mean for treatment?
- What happens between the biopsy and the first treatment?
- Do RAS and BRAF matter if the cancer has not spread?
- Four worries families raise about waiting for RAS and BRAF
- What this page cannot tell you
- Common questions about RAS and BRAF testing
The short answer
Why does my oncologist want RAS and BRAF results before starting?
Because in colon cancer that has spread, those two results decide which targeted drug can be added to chemotherapy. Some of the most useful drugs work only when RAS is normal, and a BRAF change calls for a different plan. Starting before the answer is known risks choosing a drug that cannot help.
What the result decides
Cetuximab and panitumumab block a signal called EGFR on the surface of the cancer cell. If the RAS genes (KRAS and NRAS) inside the cell are changed, the cell keeps growing whatever happens at the surface, so these drugs do nothing useful. They only bring side effects. A normal RAS result keeps them on the table. A BRAF V600E change marks a cancer that tends to move faster and needs its own approach.
Why it is ordered at the very start
First-line treatment is the plan with the most at stake, and the tissue to test is already in the laboratory from your biopsy. Ordering RAS, BRAF and MMR together, on day one of planning, means the tumour board can choose the whole first plan at once instead of changing course halfway.
These are tests on the tumour. They say nothing about what you might pass on to your children.Result by result
What does each RAS and BRAF result mean for treatment?
Your report will fall into one of these patterns. Each points the first plan in a different direction.
RAS normal, BRAF normal
Often called "RAS wild-type". EGFR-blocking drugs become an option alongside chemotherapy. Whether they are chosen first depends heavily on which side of the colon the tumour started in.
Usually means
- Left-sided tumours often get cetuximab or panitumumab
- Right-sided tumours more often get bevacizumab
RAS changed
A change in KRAS or NRAS rules out EGFR-blocking drugs. Chemotherapy with bevacizumab, which works on the tumour's blood supply, is the usual first plan. One subtype, KRAS G12C, has its own drugs for later lines.
A RAS change narrows the drug list. It does not make the cancer untreatable.BRAF V600E
This change tends to make the cancer grow faster and respond less well to standard chemotherapy. Oncologists may choose a stronger first plan and plan early for a BRAF-targeted combination.
Usually means
- Closer watching between scans
- An early talk about drug access and cost
MSI-high on the same report
If the MMR test shows the tumour is MSI-high, immunotherapy may come before chemotherapy, whatever RAS and BRAF show. This is why MMR is always ordered with them.
MSI-high is uncommon once colon cancer has spread, but when it is found it changes the first plan more than any other result. It also raises a question about Lynch syndrome for the family.
Not sure whether this applies to you?
Ask an oncologistThe order of events
What happens between the biopsy and the first treatment?
The diagnosis and the stage are confirmed
CION arranges the colonoscopy biopsy and the staging CT through accredited partners. Spread to the liver, lungs or abdominal lining is what makes RAS and BRAF urgent.
The tests are ordered on stored tissue
RAS, BRAF and MMR are requested together on the wax block from your biopsy, often with HER2 on a single gene panel. Nothing new is taken from you unless the sample is too small.
Chemotherapy may start before the result
If you are unwell or the cancer is moving quickly, chemotherapy can begin straight away. The targeted drug is then added at a later cycle, once the result is in.
The tumour board chooses the first plan
The board reads the results beside your scans, the side the tumour started on and your general health. You should hear which drug was chosen and why.
Side by side
Do RAS and BRAF matter if the cancer has not spread?
Stage 1 to 3
Stage 4 or cancer that has come back
Rarely change the treatment plan
Decide which drug joins chemotherapy
Chemotherapy after surgery is the same either way
EGFR-blocking drugs need a normal RAS result
BRAF may be run to settle a Lynch question
BRAF V600E calls for its own plan
Can be tested later on the same tissue
Wanted before first-line treatment begins
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
Four worries families raise about waiting for RAS and BRAF
"Every day spent waiting lets the cancer grow."
For most people a short wait for the right drug is safer than a fast start with the wrong one. If waiting is not safe, your oncologist starts chemotherapy and adds the targeted drug later.
"A RAS mutation means targeted therapy is impossible."
It rules out one family of drugs. Bevacizumab works whatever the RAS result, and the KRAS G12C subtype has drugs of its own for later in treatment.
"A BRAF or RAS change means it runs in the family."
Both changes arise inside the tumour and are not inherited. In an MMR-deficient tumour, a BRAF V600E change actually makes Lynch syndrome less likely.
"KRAS was tested, so RAS testing is finished."
Full RAS testing covers both KRAS and NRAS across several regions of each gene. An older or limited report may need extending before an EGFR-blocking drug is used.
Being straight with you
What this page cannot tell you
It cannot tell you which drug you should have. That depends on the result together with where the tumour started, where it has spread, whether surgery is still possible and how strong you are. Your oncologist and the tumour board weigh all of it, and why tumour side changes the drug choice explains one piece of that.
It cannot say how long the result will take
Turnaround depends on the laboratory, the method and whether the block has to be fetched from another hospital. Ask the team when the result is expected and what happens if it is late.
It cannot promise every drug is within reach
Some targeted drugs, especially the BRAF combination and the KRAS G12C medicines, are not always easy to get in India, and costs differ widely. If your result points to one of them, ask early about supply, insurance and scheme cover, so the plan does not stall later.
Who this does not apply to
If your cancer has not spread, these results rarely change your treatment. If it is MSI-high, read when immunotherapy is an option first. If the tumour is in the rectum, the rectal cancer pages cover your pathway.
The full list of colon cancer biomarkers is on its own page.Questions we are asked
Common questions about RAS and BRAF testing
Can chemotherapy start before the RAS result comes back?
Yes, when waiting is not safe. Chemotherapy can begin on its own, and cetuximab, panitumumab or bevacizumab is added once the result arrives. Many oncologists prefer to wait briefly when you are well enough, so the full plan starts together.
What does RAS wild-type mean?
It means no change was found in KRAS or NRAS in the tumour. That result allows EGFR-blocking drugs such as cetuximab and panitumumab. It is not a measure of how serious the cancer is, and it says nothing about your family.
Is a BRAF V600E result bad news?
It usually means the cancer needs a more determined plan, and it is worth knowing early. A targeted combination exists for it, described on the BRAF V600E treatment page. Your own outlook depends on far more than one gene.
Does every patient need RAS and BRAF testing?
Every patient whose cancer has spread or come back should have them. For cancer that has not spread, many oncologists hold them back because they rarely change the plan. They can be run later on the same stored tissue if needed.
Can RAS and BRAF be tested on a blood sample?
Sometimes. A liquid biopsy reads tumour DNA in the blood and helps when tissue runs out. It can miss a change when little tumour DNA is circulating, so a negative blood result is often confirmed on tissue.
Can the RAS result change over time?
The original result does not change, but after long treatment with EGFR-blocking drugs some tumours develop new RAS changes. That is one reason a repeat test, often on blood, may be suggested before the same drug is tried again.
Why was HER2 tested along with RAS and BRAF?
When RAS and BRAF are normal, a small group of tumours carry extra copies of HER2, which has its own drugs. Testing it on the same panel saves tissue and avoids a second wait later in treatment.
Can CION arrange RAS and BRAF testing?
Yes. CION's oncologists order the tests on your stored biopsy through accredited molecular laboratories, and the tumour board reads the results with your scans. Call the helpline with your biopsy report and someone will tell you what is still needed.
Your Specialists
Meet CION's colon cancer specialists. Bring your colonoscopy, scan or biopsy report.
Our surgical and medical oncologists plan colon cancer care together: which operation, whether chemotherapy is needed, and the follow-up that comes after.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Colorectal Cancer Targeted Therapy
- American Cancer Society — Colon Cancer Treatment, by Stage
- ESMO — Colorectal Cancer: A Guide for Patients
- National Cancer Institute — Targeted Therapy for Cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Which biomarkers are tested in colon cancerThe full test list, and what each one is forWhen targeted therapy is addedHow the result turns into a drug decisionHER2 and rarer targets in colon cancerThe next tests when RAS and BRAF are normalKRAS G12C mutation treatmentThe one RAS change with drugs of its own
Talk to us
Waiting on RAS and BRAF results and unsure what they will change?
Share your biopsy report and scans, and an oncologist will explain which results are pending and what each could mean for your first plan. One helpline serves every CION centre.